Dulaglutide, 923950-08-7
2 Inquiries
923950-08-7
Reagent Grade
98%
shanghai
cellmano
1g/vial
2029-12-31
Cagrilintide,SS-31, Elamipretide,Semaglutide,Tirzepatide,Retatrutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionDulaglutide, a GLP-1 receptor agonist that is administered subcutaneously once weekly, has been approved since 2014 for the treatment of adults with type 2 diabetes.Basic Info
-
Product Name:
Dulaglutide
Other Name:Dulaglutide - solution in PBS;Dulaglutide USP/EP/BP;Dulaglutide;Research Grade Dulaglutide(DHE40129);Research Grade Dulaglutide;Dulaglutide (Trulicity;LY2189265);Dulaglutide(sodium salt)
CAS No.:923950-08-7
Molecular Weight:0
EC Number:200-001-8
Color/Form:Colorless to light yellow
Categories:
Research-
Class:
GLP-1 receptor agonist (GLP-1 analog fused to human IgG4-Fc, long-acting)
Status:FDA-approved (Trulicity 2014)
Mechanism:A long-acting GLP-1 receptor agonist consisting of a modified human GLP-1 molecule (7-37) covalently linked to a modified human IgG4 Fc fragment via a small peptide linker. The Fc fusion extends the half-life to ~5 days, allowing once-weekly dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying.
Activity note:Dulaglutide is a dual-agonist with GLP-1R activation. The exact EC50 is proprietary; functional potency is comparable to other long-acting GLP-1R agonists.
Source:DrugBank: DB09095; PubChem CID 16135271.
Clinical Development:FDA:Trulicity (approved 2014-09-18)
References-
DrugBank:PubChem:Disclaimer:
Dulaglutide is FDA-approved as a prescription medicine (Trulicity) for type 2 diabetes. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Cagrilintide,SS-31, Elamipretide,Semaglutide,Tirzepatide,Retatrutide
-
Location:
Room C608, Chiyuan venture park
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
10
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
Cellmano Biotech Limited focus on researching and developing solid phase peptide synthesis methodology since 2011. Cellmano has 10 years experience in researching, developing and manufacturing peptides by solid peptide phase synthesis.
Cellmano not only provides cosmeceuticals peptide & generic peptides to the customers, but also offer peptide CMO service and custom peptides synthesis service depend on the requirement from the customers over the world. Cellmano has state-of-the-art labs armed with excellent instrument for synthesis, purify and analysis .Cellmao control the quality by checking the materials, supervising produce process and finally QC. Cellmano keep all the synthesis records , purify methods and analysis result for every batch peptide product with staff and time invovled in the archives. Synthesizing by classical solid phase mothed invented by Prof.Bruce Merrified and purifying by HPLC instrument, Cellmano supply the customers excellent peptide products with reasonable price ,while maintain high quality, to help the customers to cut down their cost and shorten the time . Cellmano is trying her best to complement the inventory for more than 2000 popular peptide products, to make sure the customers can get what they need in one week from Cellmano’s inventory. Also to saitisfy diverse request from different customers for different projects, Cellmano provide custom synthesis for peptides from mgs to kgs with the purity from crude to 98% .
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
Turkey
Dulaglutide
1 G Jun 5, 2026
United States
dulaglutide
4 Mar 11, 2026 Post an enquiry for this product